Nasdaq
$23.53▲ 0.30%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.82BShares out 1.600M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 2d agoPre-market26.10.23 19:368-KKey event#●●●#●●●#●●●
Tango Therapeutics, Inc.Bullish
Tango Therapeutics announced that its Phase 1/2 clinical trial of vopimetostat in combination with daraxonrasib demonstrated an 82% objective response rate (ORR) and an 88% 9-month progression-free survival (PFS) rate in patients with MTAP-deleted and RAS-mutant pancreatic cancer. Based on these results, the company plans to initiate a registrational Phase 3 trial as a first-line treatment in the first half of 2027 and will reduce its workforce by approximately 14% to prioritize its PRMT5-targeted therapy programs.…more
$23.53+0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 06:364Ownership
Tango Therapeutics, Inc.
Insider Adam Crystal of Tango Therapeutics reported a change in beneficial ownership of company securities effective October 1, 2026. This filing serves as a standard Form 4 disclosure regarding the insider's equity holdings.…more
$23.53+0.30%vs prev closeView filingShare - 9.24After-hours26.09.25 08:414Ownership
Tango Therapeutics, Inc.
Tango Therapeutics executive Jessica Newcomb reported a change in beneficial ownership of company securities effective September 22, 2026. This filing serves as a standard Form 4 disclosure regarding insider stock holdings.…more
$23.53+0.30%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 00:36#●●●#●●●
Tango Therapeutics Shares Fall Despite Positive Cancer Drug Data
Tango Therapeutics reported strong efficacy for its vopimetostat combination in pancreatic and lung cancer trials, yet the stock declined following the announcement. The company plans to initiate a global registrational Phase 3 trial for first-line pancreatic cancer treatment in the first half of 2027.…more
$23.53+0.30%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoPre-market26.10.23 19:30
●●●●●●●● ●●●●● ●●●●●●
Tango Therapeutics announced promising results from its Phase 1/2 study of vopimetostat in combination with daraxonrasib for pancreatic cancer. The company plans to initiate a registrational Phase 3 trial in the first half of 2027 based on these findings.…more
$23.53+0.30%vs prev close - 10.16Pre-market26.10.16 20:00
●●●●●●●● ●●●●● ●●●●●●
Tango Therapeutics will present updated Phase 1/2 clinical trial data for its cancer treatment combinations at the ESMO Congress 2026. The company will also host an investor webcast to discuss the study results during the event.…more
$23.53+0.30%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report